Marie Cullberg

1.0k total citations
27 papers, 570 citations indexed

About

Marie Cullberg is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Marie Cullberg has authored 27 papers receiving a total of 570 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 9 papers in Molecular Biology and 9 papers in Oncology. Recurrent topics in Marie Cullberg's work include PI3K/AKT/mTOR signaling in cancer (7 papers), Atrial Fibrillation Management and Outcomes (5 papers) and Pharmacogenetics and Drug Metabolism (4 papers). Marie Cullberg is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (7 papers), Atrial Fibrillation Management and Outcomes (5 papers) and Pharmacogenetics and Drug Metabolism (4 papers). Marie Cullberg collaborates with scholars based in Sweden, United Kingdom and United States. Marie Cullberg's co-authors include Bengt Larsson, Christina Keen, Margareta Puu, Kai Richter, Hristo Metev, Mohib Uddin, Paul M. O’Byrne, Parameswaran Nair, Ulf G. Eriksson and Heather Wray and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and Clinical Cancer Research.

In The Last Decade

Marie Cullberg

27 papers receiving 560 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Marie Cullberg Sweden	10	198	181	177	162	141	27	570
Wahid T. Hanna United States	11	147 0.7×	70 0.4×	84 0.5×	34 0.2×	154 1.1×	31	651
Takatoshi Fujishita Japan	13	370 1.9×	97 0.5×	99 0.6×	125 0.8×	554 3.9×	32	793
Sarah Skeoch United Kingdom	9	239 1.2×	143 0.8×	70 0.4×	60 0.4×	130 0.9×	19	631
Taku Yasui Japan	11	257 1.3×	59 0.3×	101 0.6×	32 0.2×	97 0.7×	30	636
Marleen Luten Netherlands	9	244 1.2×	66 0.4×	161 0.9×	499 3.1×	45 0.3×	12	891
Chengzeng Yin Japan	14	138 0.7×	93 0.5×	183 1.0×	116 0.7×	348 2.5×	28	653
Yeon S. Ahn United States	9	72 0.4×	157 0.9×	153 0.9×	39 0.2×	24 0.2×	10	488
Lucy Barker United Kingdom	6	631 3.2×	57 0.3×	140 0.8×	59 0.4×	56 0.4×	10	736
Naoki Umezaki Japan	14	156 0.8×	87 0.5×	87 0.5×	139 0.9×	341 2.4×	35	660
I Canavy France	6	94 0.5×	56 0.3×	157 0.9×	22 0.1×	66 0.5×	10	422

Countries citing papers authored by Marie Cullberg

Since Specialization

Citations

This map shows the geographic impact of Marie Cullberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marie Cullberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marie Cullberg more than expected).

Fields of papers citing papers by Marie Cullberg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marie Cullberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marie Cullberg. The network helps show where Marie Cullberg may publish in the future.

Co-authorship network of co-authors of Marie Cullberg

This figure shows the co-authorship network connecting the top 25 collaborators of Marie Cullberg. A scholar is included among the top collaborators of Marie Cullberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marie Cullberg. Marie Cullberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fernández‐Teruel, Carlos, Marie Cullberg, Ignacio Ferreira González, et al.. (2025). Population Pharmacokinetics and Exposure–Response Analyses for Capivasertib in Combination With Fulvestrant in Patients With Breast Cancer. Clinical and Translational Science. 18(7). e70286–e70286. 1 indexed citations

Fernández‐Teruel, Carlos, Marie Cullberg, Cath Eberlein, Simon T. Barry, & Diansong Zhou. (2024). Population Pharmacokinetics of Capivasertib in Patients with Advanced or Metastatic Solid Tumours. Clinical Pharmacokinetics. 63(8). 1191–1204. 3 indexed citations

Miller, Claire, Martin Wild, Zhoupeng Zhang, et al.. (2024). A Phase I Study To Determine the Absolute Bioavailability and Absorption, Distribution, Metabolism, and Excretion of Capivasertib in Healthy Male Participants. Drug Metabolism and Disposition. 52(9). 939–948. 4 indexed citations

Miller, Claire, Roberto Sommavilla, Cindy L. O’Bryant, et al.. (2024). Pharmacokinetic study of capivasertib and the CYP3A4 substrate midazolam in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 94(2). 223–235. 1 indexed citations

Sommavilla, Roberto, et al.. (2023). The effect of food and acid‐reducing agents on the pharmacokinetic profile of capivasertib: Results from a randomized, crossover study. British Journal of Clinical Pharmacology. 89(11). 3330–3339. 9 indexed citations

Miller, Claire, Roberto Sommavilla, Simon T. Barry, et al.. (2023). Pharmacokinetics of the Akt Serine/Threonine Protein Kinase Inhibitor, Capivasertib, Administered to Healthy Volunteers in the Presence and Absence of the CYP3A4 Inhibitor Itraconazole. Clinical Pharmacology in Drug Development. 12(9). 856–862. 9 indexed citations

Shore, Neal D., Begoña Mellado, Ralph J. Hauke, et al.. (2022). A Phase I Study of Capivasertib in Combination With Abiraterone Acetate in Patients With Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer. 21(2). 278–285. 15 indexed citations

Voronova, Veronika, Marie Cullberg, Joanna Parkinson, et al.. (2021). Concentration‐QT modelling shows no evidence of clinically significant QT interval prolongation with capivasertib at expected therapeutic concentrations. British Journal of Clinical Pharmacology. 88(2). 858–864. 6 indexed citations

Cullberg, Marie, Cecilia Arfvidsson, Bengt Larsson, et al.. (2018). Pharmacokinetics of the Oral Selective CXCR2 Antagonist AZD5069: A Summary of Eight Phase I Studies in Healthy Volunteers. Drugs in R&D. 18(2). 149–159. 19 indexed citations

10.

Dean, Emma, Udai Banerji, Jan H.M. Schellens, et al.. (2018). A Phase 1, open-label, multicentre study to compare the capsule and tablet formulations of AZD5363 and explore the effect of food on the pharmacokinetic exposure, safety and tolerability of AZD5363 in patients with advanced solid malignancies: OAK. Cancer Chemotherapy and Pharmacology. 81(5). 873–883. 18 indexed citations

11.

Paik, Paul K., Ronglai Shen, Michael F. Berger, et al.. (2017). A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers. Clinical Cancer Research. 23(18). 5366–5373. 115 indexed citations

12.

O’Byrne, Paul M., Hristo Metev, Margareta Puu, et al.. (2016). Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial. The Lancet Respiratory Medicine. 4(10). 797–806. 196 indexed citations

13.

Förster, Karin, Anneliese Linnhoff, Beatrix Bálint, et al.. (2015). The safety and tolerability of oral AZD5069, a selective CXCR2 antagonist, in patients with moderate-to-severe COPD. Pulmonary Pharmacology & Therapeutics. 31. 36–41. 73 indexed citations

14.

Cullberg, Marie, Heather Wray, & Bengt Larsson. (2014). Effect of the CYP3A4 inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of AZD5069, an oral CXCR2 antagonist. European Respiratory Journal. 44(Suppl 58). P961–P961. 1 indexed citations

15.

Johansson, Susanne, et al.. (2011). Single-dose pharmacokinetics, pharmacodynamics and safety of AZD0837, a novel oral direct thrombin inhibitor, in young healthy male subjects. International Journal of Clinical Pharmacology and Therapeutics. 49(4). 258–267. 15 indexed citations

16.

Cullberg, Marie, et al.. (2005). Pharmacokinetics of ximelagatran and relationship to clinical response in acute deep vein thrombosis. Clinical Pharmacology & Therapeutics. 77(4). 279–290. 23 indexed citations

17.

Johansson, Susanne, et al.. (2005). No effect of encapsulation on the pharmacokinetics of warfarin. Biopharmaceutics & Drug Disposition. 26(3). 121–127. 2 indexed citations

18.

Fager, Gunnar, et al.. (2003). Pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, are not influenced by acetylsalicylic acid. European Journal of Clinical Pharmacology. 59(4). 283–289. 25 indexed citations

19.

Cullberg, Marie, et al.. (2001). Population modelling of the effect of inogatran, at thrombin inhibitor, on ex vivo coagulation time (APTT) in healthy subjects and patients with coronary artery disease. British Journal of Clinical Pharmacology. 51(1). 71–79. 15 indexed citations

20.

Nyman, Leena, et al.. (1998). Encapsulation of Commercially Available Losartan for Blinding Purposes Does Not Affect its Bioavailability. Clinical Drug Investigation. 15(4). 361–365. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact